Compare Medpace Holdings Inc (MEDP) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Koninklijke Philips NV — how do they compare? Medpace Holdings Inc trades at $534.03 (market cap $15.08B), while Koninklijke Philips NV trades at $26.58 (market cap $26.19B). The key difference: Koninklijke Philips NV is the larger of the two by market cap, and Koninklijke Philips NV pays a 3.79% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | PHG | |
|---|---|---|
Market Cap | $15.08B | $26.19B |
Sector | Technology | Health |
52-Week High | $620.59 | $32.91 |
52-Week Low | $308.88 | $24.54 |
Enterprise Value | $14.55B | $32.46B |
Dividend Yield | — | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
PHG trades at $26.80, down 0.56% with bearish technical signals. The company shows improved fundamentals with net income turning positive to $895M in 2025 after previous losses, though revenue declined slightly to $17.83B. Analyst consensus is mixed with 40.9% buy ratings but technical indicators show selling pressure. Recent developments include FDA clearances for AI-powered medical devices and strategic healthcare partnerships.
PHG presents a turnaround story with profitability recovery but faces execution risks amid competitive pressures. The stock offers value at reasonable valuations (P/E 23.67, P/S 1.29) but requires monitoring of revenue stabilization and AI product adoption. Near-term catalyst includes Q2 2026 earnings with expected EPS of $0.40.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
